Major Crackdown on Production and Sale of Counterfeit E-Cigarettes

Regulations by 2FIRSTS.ai
Nov.24.2023
Major Crackdown on Production and Sale of Counterfeit E-Cigarettes
Police in Shiyan, Hubei province, China, have busted a major e-cigarette production and sales case, arresting 20 suspects and seizing over CNY 100 million worth of counterfeit products.

According to a statement released by the Dongyue Sub-bureau of the Public Security Bureau (PSB) in Shiyan, Hubei Province on November 23rd, a major case involving the production and sale of counterfeit e-cigarettes across multiple provinces and cities has been successfully cracked. The authorities have apprehended 20 suspects involved in the case, with the total value of the products involved exceeding 100 million yuan.

Major Crackdown on Production and Sale of Counterfeit E-Cigarettes
Translation: Production site of e-cigarettes. Image provided by the Shiyan police.

 

In March 2023, staff members of the Tenyan Tobacco Sales Bureau discovered the sale of fruit-flavored e-cigarettes (pods) within the urban area. They immediately launched an investigation and identified Liu as a suspect for selling tobacco products without a license. Subsequently, they reported the matter to the police.

 

After receiving a report, the Economic Investigation Brigade of Dongyue Sub-bureau proceeded to initiate a formal investigation into Liu's case. On April 20th, the specialized police officers apprehended Liu and his superior, Xiang, inside a residential property in Wuhan, where they were engaged in a transaction. A total of over 40,000 counterfeit e-cigarette pods and 136 smoking accessories were seized at the scene.

 

After the arrest of two individuals, the police successfully identified two subordinate distributors and their superior, Wu Mou, located in Wuxi, Jiangsu Province through interrogations and investigative analysis. In order to gather further evidence against Wu Mou, the specialized police team conducted on-site investigations in Wuxi. Ultimately, six suspects involved in illegal business activities, with Wu Mou as the leader, were apprehended. Additionally, three shops and three storage locations under their names were searched, resulting in the seizure of over 20,000 counterfeit e-cigarette pods and one transportation vehicle.

 

In a situation where Wu was extremely uncooperative, the investigating police analyzed and assessed the logistics and financial flows they had already obtained. As the evidence chain became clearer, Wu's psychological defenses were gradually breached, and he confessed to the process of contacting Feng and Qiu to obtain goods.

 

As a result, the task force immediately traveled to Dongguan to carry out an investigation, successfully identifying several suspected criminals, including Feng and Qiu. However, no finished fruit-flavored e-cigarette (pod) products were found at the production site. After more than two months of investigation, the police gradually unraveled information regarding the organization structure and production patterns of the criminal gang.

 

On July 26th, under the careful coordination of the public security authorities and tobacco department in multiple locations, the special task force of the Dongyue Sub-bureau and staff from the tobacco department carried out simultaneous operations in Dongguan, Zhongshan, and Zhanjiang, Guangdong. They successfully arrested two suspects involved in the case, dismantled three e-cigarette manufacturing sites, and shut down two storage and distribution centers. This operation effectively disrupted the entire supply chain of e-cigarette production, sales, and raw material processing related to this case.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14